Camilla Roberti | Department of Medicine and Surgery, University of Parma, Italy
Identifiaction of High-Risk Recurrence Patients in Stage I-III NSCLC through Integration of Radiological Tumor Volume and Minimal Residual Disease
Previous
Previous
Early Tumor Burden Dynamics on CT Scans to Predict Clinical Outcome In Advance NSCLC Patients Undergoing First-line Immune Checkpoint Inhibitors or First-line Chemo-Immunotherapy
Next
Next